845256-59-9

Usage

Uses

Used in Pharmaceutical Industry:
Benzyl 3-fluoro-4-oxopiperidine-1-carboxylate is used as an intermediate in the synthesis of various organic compounds for the development of new drugs. Its unique chemical structure allows for the creation of novel drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
Benzyl 3-fluoro-4-oxopiperidine-1-carboxylate is used as a building block for the development of new pesticides. Its unique chemical properties can contribute to the design of innovative agrochemicals with improved efficacy and selectivity.
Used in Medicinal Chemistry Research:
Due to its potential biological activity, benzyl 3-fluoro-4-oxopiperidine-1-carboxylate is of interest for medicinal chemistry research. It can be studied for its interactions with biological targets, leading to the discovery of new therapeutic agents or understanding its mode of action in biological systems.

Upstream product

• 1070896-59-1 3-fluoropiperidin-4-one hydrochloride 
• 501-53-1 benzyl chloroformate 
• 6099-86-1 cyclohexylmethyl chlorocarbonate 
• 355006-62-1 C₁₅H₂₀FNO₄ 
• 913574-94-4 benzyl 4-((tert-butyldimethylsilyl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate 
• 1147998-34-2 phenylmethyl 4-[(trimethylsilyl)oxy]-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 

Downstream Products

• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 913574-95-5 trans benzyl 3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 955029-44-4 (syn)-3-fluoro-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 1147112-66-0 benzyl (3R,4S)-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 1147112-65-9 benzyl (3S,4R)-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 373604-29-6 3-fluoropiperidin-4-ol 
• 1400707-07-4 (3R,4S)-4-cyclopropylamino-3-fluoro-piperidine-1-carboxylic acid benzyl ester 
• 1400707-06-3 (3S,4R)-4-cyclopropylamino-3-fluoro-piperidine-1-carboxylic acid benzyl ester 
• 1209780-78-8 benzyl (3S,4S)-3-fluoro-4-((4-nitrobenzoyl)oxy)piperidine-1-carboxylate 
• 1233932-54-1 C₁₅H₁₉FN₂O₃ 

Relevant academic research and scientific papers

NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING PHARMACOKINETICS OF DRUG

Imidazole derivatives of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one imidazole derivative are disclosed. The imidazole derivatives are effective to inhibit CYP450 3A and can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.